What is IMVT's current stock price?

IMVT (Immunovant, Inc.) is currently trading at $33.78 with a market cap of $6.94B.

What sector is Immunovant, Inc. in?

Immunovant, Inc. (IMVT) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is IMVT a good stock to buy?

Analysts have a Buy consensus on IMVT with a price target of $43.67. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

IMVT Immunovant, Inc.

Healthcare

$33.78+0.00%OpenMarket Cap: $6.94B

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

8.16

P/S

0.00

EV/EBITDA

-11.59

DCF Value

$4.93

FCF Yield

-5.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-68.2%

ROA

-52.8%

ROIC

-62.5%

Financials

View All

Period	Revenue	Net Income	EPS
Q4 null	$0.00	$-147.9M	$—
FY null	$0.00	$-505.6M	$—
Q3 null	$0.00	$-110.6M	$—
Q2 null	$0.00	$-126.5M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$43.67

Target (Median)

$41.00

Target Range

$40.00 - $50.00

2 Strong Buy11 Buy5 Hold0 Sell0 Strong Sell

Truist SecuritiesHold

2026-05-22

B of A SecuritiesBuy

2026-05-21

HC Wainwright & Co.Buy

2026-05-21

Goldman SachsNeutral

2026-04-15

HC Wainwright & Co.Buy

2026-02-10

Trading Activity

Insider Trades

View All

Gloria Melanieofficer: Chief Operating Officer

SellFri May 22

Gloria Melanieofficer: Chief Operating Officer

SellFri May 22

Gloria Melanieofficer: Chief Operating Officer

SellFri May 22

Pande Atuldirector

SellWed May 20

Pande Atuldirector

SellWed May 20

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.70

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Peers

DYN